Terms: = Lung cancer AND CHD4, Mi2-BETA, 1108, ENSG00000111642, Mi-2b, DKFZp686E06161, Q14839
51 results:
1. Trends in lung cancer diagnosis and care among visible minorities and non-visible minorities in Canada.
McFadgen H; Lethbridge L; Dunbar M; Plourde M
Cancer Causes Control; 2024 Apr; 35(4):575-582. PubMed ID: 37932475
[TBL] [Abstract] [Full Text] [Related]
2. Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing.
Huang L; Lou N; Xie T; Tang L; Han X; Shi Y
Cancer Immunol Immunother; 2023 Oct; 72(10):3259-3277. PubMed ID: 37458771
[TBL] [Abstract] [Full Text] [Related]
3. Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation.
Guo XJ; Cai XT; Rong ZX; Zhang YP; Wen YX; Bai X; Wang J; Fu QJ; Guo ZQ; Long LL; Ma SC; Tang XR; Liu L; Guan J; Dong ZY; Wu DH
BMC Med; 2023 Jan; 21(1):6. PubMed ID: 36600276
[TBL] [Abstract] [Full Text] [Related]
4. Minimum Volume Standards for Surgical Care of Early-Stage lung cancer: A Cost-Effectiveness Analysis.
Subramanian MP; Yang Z; Chang SH; Willis D; Zhang J; Semenkovich TR; Heiden BT; Kozower BD; Kreisel D; Meyers BF; Patterson GA; Nava RG; Puri V
Ann Thorac Surg; 2022 Dec; 114(6):2001-2007. PubMed ID: 35780816
[TBL] [Abstract] [Full Text] [Related]
5. Practice patterns among oncologists participating in the oncology care model after three years.
Walker B; Wilfong L; Frytak J; Robert N
J Cancer Policy; 2021 Sep; 29():100294. PubMed ID: 35559949
[TBL] [Abstract] [Full Text] [Related]
6. Differences in medical costs among urban lung cancer patients with different health insurance schemes: a retrospective study.
Li Y; Yang Y; Yuan J; Huang L; Ma Y; Shi X
BMC Health Serv Res; 2022 May; 22(1):612. PubMed ID: 35524258
[TBL] [Abstract] [Full Text] [Related]
7. Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors.
Gefard-Gontier E; Markich R; Zysman M; Veillon R; Daste A; Domblides C; Sionneau B; Gross-Goupil M; Lefort F; Prey S; Dutriaux C; Gerard E; Dousset L; Pham-Ledard A; Beylot-Barry M; Schaeverbeke T; Kostine M
Cancer Immunol Immunother; 2022 Nov; 71(11):2609-2618. PubMed ID: 35305123
[TBL] [Abstract] [Full Text] [Related]
8. Clinical characteristics and survival analysis of liver transplantation in patients with alcoholic liver disease: A single-center retrospective study.
Yang Y; Wang X; Cao J; Li J
Transpl Immunol; 2022 Jun; 72():101569. PubMed ID: 35248726
[TBL] [Abstract] [Full Text] [Related]
9. Alveolar soft tissue sarcoma: a report of 50 cases at a single institution.
Zhao P; Li H; Ren H
Acta Chir Belg; 2023 Aug; 123(4):375-383. PubMed ID: 35236247
[TBL] [Abstract] [Full Text] [Related]
10. lung-RADS Category 3 and 4 Nodules on lung cancer Screening in Clinical Practice.
Mendoza DP; Petranovic M; Som A; Wu MY; Park EY; Zhang EW; Archer JM; McDermott S; Khandekar M; Lanuti M; Gainor JF; Lennes IT; Shepard JO; Digumarthy SR
AJR Am J Roentgenol; 2022 Jul; 219(1):55-65. PubMed ID: 35080453
[No Abstract] [Full Text] [Related]
11. [Affinity chromatography based phosphoproteome research on lung cancer cells and its application].
Zhang B; Wang C; Guo M; Xiao H
Se Pu; 2021 Jan; 39(1):77-86. PubMed ID: 34227361
[TBL] [Abstract] [Full Text] [Related]
12. Cytoplasmic ADP-ribosylation levels correlate with markers of patient outcome in distinct human cancers.
Aimi F; Moch H; Schraml P; Hottiger MO
Mod Pathol; 2021 Aug; 34(8):1468-1477. PubMed ID: 33742140
[TBL] [Abstract] [Full Text] [Related]
13. chd4 mediates proliferation and migration of non-small cell lung cancer via the RhoA/ROCK pathway by regulating PHF5A.
Xu N; Liu F; Wu S; Ye M; Ge H; Zhang M; Song Y; Tong L; Zhou J; Bai C
BMC Cancer; 2020 Mar; 20(1):262. PubMed ID: 32228507
[TBL] [Abstract] [Full Text] [Related]
14. Prospective clinical trial evaluating vulnerability and chemotherapy risk using geriatric assessment tools in older patients with lung cancer.
Tsubata Y; Shiratsuki Y; Okuno T; Tanino A; Nakao M; Amano Y; Hotta T; Hamaguchi M; Okimoto T; Hamaguchi S; Kurimoto N; Nishiyama Y; Kimura T; Iwata H; Tsumoto S; Isobe T
Geriatr Gerontol Int; 2019 Nov; 19(11):1108-1111. PubMed ID: 31746525
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic Significance of Liver Metastasis in Durvalumab-Treated lung cancer Patients.
Sridhar S; Paz-Ares L; Liu H; Shen K; Morehouse C; Rizvi N; Segal NH; Jin X; Zheng Y; Narwal R; Gupta A; Dennis PA; Ye J; Mukhopadhyay P; Higgs BW; Ranade K
Clin Lung Cancer; 2019 Nov; 20(6):e601-e608. PubMed ID: 31327642
[TBL] [Abstract] [Full Text] [Related]
16. Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.
Antonia SJ; Balmanoukian A; Brahmer J; Ou SI; Hellmann MD; Kim SW; Ahn MJ; Kim DW; Gutierrez M; Liu SV; Schöffski P; Jäger D; Jamal R; Jerusalem G; Lutzky J; Nemunaitis J; Calabrò L; Weiss J; Gadgeel S; Bhosle J; Ascierto PA; Rebelatto MC; Narwal R; Liang M; Xiao F; Antal J; Abdullah S; Angra N; Gupta AK; Khleif SN; Segal NH
J Thorac Oncol; 2019 Oct; 14(10):1794-1806. PubMed ID: 31228626
[TBL] [Abstract] [Full Text] [Related]
17. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
18. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
[TBL] [Abstract] [Full Text] [Related]
19. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
Segal NH; Ou SI; Balmanoukian A; Fury MG; Massarelli E; Brahmer JR; Weiss J; Schöffski P; Antonia SJ; Massard C; Zandberg DP; Khleif SN; Xiao F; Rebelatto MC; Steele KE; Robbins PB; Angra N; Song X; Abdullah S; Butler M
Eur J Cancer; 2019 Mar; 109():154-161. PubMed ID: 30731276
[TBL] [Abstract] [Full Text] [Related]
20. Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease - analysis of institutional and population data.
Yoon JH; Nouraie M; Chen X; Zou RH; Sellares J; Veraldi KL; Chiarchiaro J; Lindell K; Wilson DO; Kaminski N; Burns T; Trejo Bittar H; Yousem S; Gibson K; Kass DJ
Respir Res; 2018 Oct; 19(1):195. PubMed ID: 30285867
[TBL] [Abstract] [Full Text] [Related]
[Next]
